Would you offer consolidative durvalumab after chemoRT for an isolated mediastinal recurrence of NSCLC that occurred during adjuvant pembrolizumab given for the initial lung cancer?
Would the recurrence while already on the checkpoint inhibitor sway you from offering durvalumab?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Colorado Cancer Center
Answered on
No, I would not
Join for free or sign in to see the full answer